Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV Infection

In brief

HIV-infected children, youth, and adults have lower bone mineral density (BMD) than would be expected for HIV-uninfected people of similar age, weight and race. As the majority of perinatally HIV-infected U.S. children are entering or in adolescence, the potential for HIV-related impaired BMD during the adolescent peak of bone mass acquisition is of particular concern. The primary purpose of this study was to compare changes from pre-treatment levels of BMD of the lumbar spine after 24 and 48 weeks of alendronate treatment with placebo in HIV-infected children and adolescents.

Key facts

Study ID
NCT00921557
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
52
Starts
2009-11-01
Expected to finish
2017-01-01
Last updated by the study team
2021-11-05

Who can join

Age: 11 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.